Opinion of the Transparency Council – quetiapinum
At its meeting on 22 April 2025, the Transparency Council adopted opinion No. 70/2025 on the reimbursement of medicines containing the active substance quetiapinum for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics, i.e. mental disorders other than those listed in the SPC in patients with dementia